Análisis inmunohistoquimico y molecular de los genes de reparación en cáncer testicular

Alessandro Palma, E. Riquelme Sánchez, María Maroto, Luís Pino, Fredrick S. LeachActas 2005 · DOI

Abstract

The correction of mismatched nucleotides during DNA replication (mismatch repair system) can determine different biological and clinical potentials in tumors. This study investigates the immunohistochemical expression of repair genes (hMLH1 and hMSH2) in 118 cases of testicular cancer across various histological types. The researchers correlated expression levels with microsatellite instability (MSI) and clinical outcomes. Results showed that hMSH2 expression correlates with tumor stage ($p < 0.001$), while cancer-specific survival correlates with hMLH1 expression ($p = 0.036$). MSI was detected in 94% and 92% of cancers with low hMLH1 and hMSH2 expression, respectively. The study concludes that MMR gene expression and genetic instability frequency define testicular cancers with distinct molecular properties and prognoses, offering a valuable tool for patient management alongside traditional histology.

Introduction

Testicular germ cell tumors are histologically diverse. While many respond well to treatment, a subset remains aggressive and prone to relapse. Current clinical management relies heavily on histology and serum markers, which may not fully capture the underlying biological aggressiveness of a tumor. This study addresses this gap by examining the Mismatch Repair (MMR) system, which functions as a DNA "spell-checker." Failure in this system leads to Microsatellite Instability (MSI), a hallmark of genomic instability. The researchers aimed to determine if MMR protein expression and MSI could serve as predictive molecular markers for disease progression in testicular cancer.

Methods

The study analyzed 118 testicular tumor specimens collected between 1995 and 1999. A multi-modal approach was employed:

  1. Immunohistochemistry (IHC): Monoclonal antibodies were used to assess hMLH1 and hMSH2 protein expression in paraffin-embedded tissues, categorized as "low" or "high."
  2. Molecular Analysis: Tumor and normal tissues were microdissected and compared. DNA was amplified via PCR using 10 specific markers (e.g., BAT 25, BAT 26, D3S1289) to detect MSI and Loss of Heterozygosity (LOH).
Molecular analysis showing Loss of Heterozygosity (LOH) and Microsatellite Instability (MSI) across different markers.
  1. Statistical Correlation: Chi-square and Fisher’s exact tests linked molecular findings to clinical outcomes, including tumor stage and patient survival.

Results and Key Insights

The researchers found a strong correlation between protein expression and genetic stability. Specifically, over 90% of tumors with low hMLH1 or hMSH2 expression exhibited high MSI.

Gene-Specific Clinical Correlations

The two repair genes were found to correlate with different clinical parameters:

  • hMSH2: Low expression was a strong indicator of advanced pathologic stage ($p < 0.001$).
  • hMLH1: Low expression was significantly tied to decreased cancer-specific survival ($p = 0.036$).

Histological Variation

Expression levels varied significantly across histological types. For instance, pure seminomas showed significantly higher hMSH2 expression compared to other subtypes, suggesting distinct repair dependencies or baseline genomic stability levels.

Distribution of hMLH1 and hMSH2 expression levels (High/Low) across different histological types of testicular cancer.

The High-Risk Molecular Signature

A specific "high-risk" profile—characterized by low MMR expression and high genetic instability—was identified in approximately 9% of the cohort. This subgroup demonstrated significantly worse clinical outcomes, including higher rates of relapse ($p = 0.01$) and cancer-specific death ($p = 0.04$).

Discussion and Conclusion

The degree of MMR gene expression and the frequency of genetic instability define testicular cancers with distinct molecular properties and prognostic outlooks. These molecular markers, when used alongside traditional histology and serological markers, can significantly enhance risk stratification and patient management.

While promising, the study notes limitations such as the inherent subjectivity of IHC grading and the need for larger multi-center validation. Future work should focus on identifying the specific mutations driving MMR failure and exploring how these markers can guide personalized, more aggressive treatment for high-risk patients.

Summary updated

Abstract

ANALISIS INMUNOHISTOQUIMICO Y MOLECULAR DE LOS GENES DE REPARACION EN CANCER TESTICULARLa corrección de los nucleótidos mal incorporados durante la replicación del ADN (sistema de reparación de genes) puede determinar un potencial biológico y clínico diferente en los tumores.En este trabajo investigamos la expresión inmunohistoquímica de los genes de reparación en cáncer de testículo en los distintos tipos histológicos, correlacionando el grado de expresión con la presencia de inestabilidad microsatélite y correlacionando ambas con la evolución clínica.Pacientes y método: 118 casos de tumores testiculares fueron analizados molecularmente realizando inmunohistoquímica para hMLH1 y hMSH2.El análisis de inestabilidad microsatélite y LOH se realizó comparando ADN micro disecado de tejido tumoral y normal, el que fue amplificado mediante PCR con 10 marcadores preestablecidos.Resultados: El grado de expresión de hMSH2 se correlaciona con el estadio del tumor (p<0,001) mientras que la sobreviva cáncer específica se correlaciona con el grado de expresión de hMLH1 (p=0,036).Inestabilidad microsatélite se detectó en un 94% y 92% de los cánceres con baja expresión de hMLH1 y hMSH2 respectivamente.La recaída y muerte cáncer específica se correlacionan con el grado de inestabilidad genética (p=0,01, p=0,04).Un 9% de los tumores presentan una bajo grado de expresión de los genes de reparación, inestabilidad microsatélite y un mal pronóstico.Conclusiones: El grado de expresión de los genes de reparación así como la frecuencia de inestabilidad logran definir cánceres testiculares con diferentes propiedades moleculares y diferente pronóstico.Los genes de reparación usados en conjunto con la histología, los marcadores serológicos pueden ser determinantes en el manejo de los pacientes con tumores testiculares.
BibTeX
@inproceedings{palma2005analisis,
  author = {Alessandro Palma and E. Riquelme Sánchez and María Maroto and Luís Pino and Fredrick S. Leach},
  title = {{Análisis inmunohistoquimico y molecular de los genes de reparación en cáncer testicular}},
  booktitle = {Actas},
  year = {2005},
  doi = {10.4321/s0210-48062005000200009},
}
Figure